Pharmacology News

Outpatient diverticulitis treatment with amoxicillin-clavulanate was “just as effective” as treatment with a combination of metronidazole and a fluoroquinolone, a researcher told Healio Primary Care.

A combined therapy of phosphodiesterase type 5 — or PDE5 — inhibitors and other treatments was associated with improved outcomes in patients with erectile dysfunction, according to research published in JAMA Network Open.

In the early days of the COVID-19 pandemic, the Drug Enforcement Administration announced it would temporarily ease restrictions on access to buprenorphine for opioid use disorder.

Now is a time of transition in our nation. As physicians, regardless of our background or upbringing, we hold positions of power and privilege in society. We must use our power to give voice to our patients and communities.

Access to medical and recreational cannabis dispensaries was associated with reductions in opioid-related mortality in counties where cannabis is legal in the United States, according to research published in BMJ.

Adults with obesity assigned the GLP-1 receptor agonist semaglutide experienced substantial weight loss compared with placebo, with more than half of participants losing 15% of body weight, according to data from the STEP 1 study.

Klisyri, an FDA-approved Src kinase signaling inhibitor, was superior to placebo for the treatment of actinic keratoses, according to findings from two double-blind randomized trials published in The New England Journal of Medicine.

Biosimilar use among Medicare fee-for-service beneficiaries seems to depend most on practice setting and hospital ownership status, with few patient or physician characteristics linked to usage, according to data in JAMA Network Open.

Individuals taking prescription opioids for chronic pain may face difficulties scheduling new patient appointments at primary care clinics and continuing to receive their prescriptions, according to research published in Pain.

Entasis Therapeutics recently announced the availability of an expanded access program for sulbactam-durlobactam, an investigational treatment for Acinetobacter baumannii infections, including carbapenem- and multidrug-resistant strains.